Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorder.


Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 04 2023
Historique:
received: 04 10 2022
revised: 15 02 2023
accepted: 16 02 2023
pubmed: 10 3 2023
medline: 22 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

Hypomagnesemia (hypoMg) has not yet been extensively studied in alcohol use disorder (AUD) . We hypothesize that chronic, excessive alcohol consumption favors oxidative stress and pro-inflammatory alterations that may be exacerbated by hypoMg. The objective of this study was to analyze the prevalence and associations of hypoMg in AUD. Cross-sectional study in patients admitted for a first treatment of AUD in six tertiary centers between 2013 and 2020. Socio-demographic, alcohol use characteristics, and blood parameters were ascertained at admission. 753 patients (71% men) were eligible; age at admission was 48 years [IQR, 41-56 years]. Prevalence of hypoMg was 11.2%, higher than that observed for hypocalcemia (9.3%), hyponatremia (5.6%), and hypokalemia (2.8%). HypoMg was associated with older age, longer duration of AUD, anemia, higher erythrocyte sedimentation rate, gamma-glutamyl transpeptidase, glucose levels, advanced liver fibrosis (FIB-4 ≥3.25) and estimated glomerular filtration rate (eGFR) < 60 mL/min. In multivariate analysis, advanced liver fibrosis (OR, 8.91; 95% CI, 3.3-23.9) and eGFR < 60 mL (OR, 5.2; 95% CI, 1.0-26.2) were the only factors associated with hypoMg. Mg deficiency in AUD is associated with liver damage and glomerular dysfunction suggesting that both comorbidities should be assessed in the course of serum hypoMg.

Identifiants

pubmed: 36893509
pii: S0376-8716(23)00060-1
doi: 10.1016/j.drugalcdep.2023.109822
pii:
doi:

Substances chimiques

Magnesium I38ZP9992A

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109822

Investigateurs

CohRTA Study (C)
Coordinating Center (C)
Arantza Sanvisens (A)
Paola Zuluaga (P)
Daniel Fuster (D)
Anna Hernández-Rubio (A)
Magí Farré (M)
Esther Papasseit (E)
Clara Pérez-Mañá (C)
Lourdes Poyatos (L)
Nuria García-Marchena (N)
Enric Abellí (E)
Robert Muga (R)
Antonio Short (A)
Catalina Moranta (C)
Rafael Blanes (R)
Gabriel Rubio (G)
Ana Sion (A)
Laia Miquel (L)
Lluisa Ortega (L)
Pol Bruguera (P)
Elsa Caballeria (E)
Ana Messeguer (A)
Marta Torrens (M)
Francina Fonseca (F)
Juan Ignacio Mestre-Pinto (J)
María Alías (M)
Fernando Dinamarca (F)
Ferran Bolao (F)
Fernando Rodríguez de Fonseca (F)
Francisco Javier Pavón-Morón (F)
Pedro Araos (P)
María Flores-López (M)
Antonia Serrano (A)
Miguel Marcos (M)
Candelaria Martín (C)
Onán Pérez-Hernández (O)
Jorge Manzanares (J)
Lucía Illescas (L)

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement None.

Auteurs

Anna Hernández-Rubio (A)

Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol - IGTP, Universitat Autònoma de Barcelona, Badalona, Spain.

Arantza Sanvisens (A)

Epidemiology Unit and Girona Cancer Registry, Institut Català d'Oncologia, IDIBGI, Girona, Spain.

Lucía Barbier-Torres (L)

Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Ángeles, California, EE.UU.

Rafael Blanes (R)

Department of Psychiatry, Alcohol Unit, Hospital Universitari Son Espases - IdISPa, Palma de Mallorca, Spain.

Laia Miquel (L)

Department of Psychiatry, Hospital Clínic de Barcelona - IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

Marta Torrens (M)

Department of Neuropsychiatry and Addictions, Hospital del Mar - IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain.

Gabriel Rubio (G)

Department of Psychiatry, Hospital Universitario 12 de Octubre - Instituto i + 12, Universidad Complutense de Madrid, Madrid, Spain.

Ferran Bolao (F)

Department of Internal Medicine, Hospital Universitari de Bellvitge- IDIBELL, L'Hospitalet de Llobregat, Spain.

Paola Zuluaga (P)

Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol - IGTP, Universitat Autònoma de Barcelona, Badalona, Spain.

Daniel Fuster (D)

Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol - IGTP, Universitat Autònoma de Barcelona, Badalona, Spain.

Fernando Rodríguez de Fonseca (F)

IBIMA Biomedical Research Institut - Málaga, Málaga, Spain.

Magí Farré (M)

Department of Clinical Pharmacology, Hospital Universitari Germans Trias i Pujol - IGTP, Universitat Autònoma de Barcelona, Badalona, Spain.

Robert Muga (R)

Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol - IGTP, Universitat Autònoma de Barcelona, Badalona, Spain. Electronic address: rmuga.germanstrias@gencat.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH